THE ULTIMATE EVOLUTION IN DES TECHNOLOGY FOR DIABETICS: CRE8 EVO
|
|
- Marcus Goodwin
- 6 years ago
- Views:
Transcription
1 The ultimate EVOlution in DES technology for diabetics: Cre8 EVO THE ULTIMATE EVOLUTION IN DES TECHNOLOGY FOR DIABETICS: CRE8 EVO Rafael Romaguera, MD Barcelona Spain Rafael Romaguera, MD Hospital de Bellvitge Barcelona
2 Conflicts of interest Speaker honoraria: Abbott vascular, Alvimedica, St Jude Medical
3 Diabetes: A global emergency
4 Lower -limus DES efficacy in Diabetes Direct resistance of VSMCs to limus drugs non-diabetic diabetic Overweight/ Obese patients (90% of diabetics): Effect of Leptin in Pathological status (Hyperleptinaemia) non-diabetic diabetic 9/10 times higher -limus concentration is needed in the diabetic cell to achieve similar inhibition seen in non-diabetic one
5 Unique technology for very high efficacy in diabetes: Abluminal Reservoir Technology Amphilimus formulation
6 Amphilimus formulation Sirolimus Fatty Acid R Immunosuppressant Anti-proliferative action Anti-microbial Inhibitor of inflammatory cell activities High potency Proprietary technology Sirolimus and Fatty Acid are eluted together Combined effect!!! Sustained drug elution timing Modulated drug bioavailability Raised homogeneous drug distribution Enhanced drug stability
7 The key role of Fatty Acids in diabetic cells 30% NON-Diabetic cell 70% DIABETIC cell 100% FATTY ACID + SIROLIMUS Two pathways for ATP generation: 1. Glucose pathway (30%) 2. Fatty acid pathway (70%) Membrane protein overexpression leads to higher fatty acids bindings/ traslocation. Membrane Fatty Acid Transporters as Regulators of Lipid Metabolism: Implications for Metabolic Disease - Glatz J; 2010 Physiol Rev 90:
8 Abluminal Reservoir Technology Alvimedica utilizes a proprietary polymer-free drug release system constituted by reservoirs on the stent's abluminal surface ARTERIAL WALL Drug elution is controlled and directed exclusively towards the vessel wall BLOOD FLOW Lack of any polymer Lack of any drug
9 Abluminal Reservoir Technology Abluminal Reservoir is the ONLY polymer-free technology able to provide the same elution kinetic obtained by the most effective polymeric DES. Results obtained with below reservoir design: Peak drug tissue concentration during the first days 50% drug elution in approximately 18 days 65%-70% drug elution within 30 days Complete drug elution within 90 days
10 Amphilimus TM eluting DES: Results in Patients with Diabetes
11 RESERVOIR Trial AES = Cre8 EES = Xience family Primary endpoint: Neointimal volume obstruction Romaguera R, et al. JACC Cardiovasc Interv. 2016; 9: Hospital Clínico San Carlos Madrid
12 Primary endpoint: Neointimal Volume Obstruction p for non-inferiority = AES = Cre8 EES = Xience family Romaguera R, et al. JACC Cardiovasc Interv. 2016; 9: Hospital Clínico San Carlos Madrid
13 Late Lumen Loss (9months) Romaguera R, et al. JACC Cardiovasc Interv. 2016; 9: Hospital Clínico San Carlos Madrid
14 Participate Study Design Real world" patients with ischemic myocardial symptoms related to de novo coronary artery lesions, treated with Cre patients 30 European Sites PI: A. Colombo - Italy Pre-specified diabetic subgroup Diabetics patients submitted to angio FU OBJECTIVE: evaluate the safety and efficacy performances of Cre8, in patients comparable to the everyday s clinical practice population, with a specific focus on diabetics subjects PRIMARY ENDPOINT: 6-month incidence of clinical composite endpoint: Cardiac death/ Target vessel MI/ Clinically indicated TLR Clinical FU Angiographic FU (diabetic pre-spec. group) 1M 6M Y
15 Diabetic Population - 12month results - Overall Population - 12month results - Device-Oriented MACE at 1year 3% 12month MACE* = CD + TV MI + CI TLR 2,8% CI: 1.93% ; 3.91% 2% 1% 0,9% 0,9% 1,0% CI: 0.47% ; 1.68% CI: 0.53% ; 1.79% CI: 0.41% ; 1.57% 0% 5% 4% Cardiac Death Target Vessel MI CI TLR MACE 4,7% CI: 2.55% ; 7.63% 3% 2% 1% 1,7% 1,7% CI: 0.55% ; 3.90% CI: 0.55% ; 3.90% 1,4% CI: 0.37% ; 3.42% 0% Cardiac Death Target Vessel MI CI TLR MACE *MACE as percent frequencies of the device oriented clinical composite of CD, TV MI, CI TLR up to 6 months - ITT population - Diabetic population (N = 296) - Adjudicated events
16 Cre8 in-stent LLL results in diabetics 0,50 0,40 0,30 0,20 0,10 0,12 ±0,29 0,16 ±0,13 0,14 ±0,24 0,00 NEXT (diabetic subgroup) PARTICIPATE (diabetic subgroup) RESERVOIR Randomized study All-Comers study Randomized study in DM Company sponsored studies Independent study
17 The latest clinical evidence of Amphilimus TM efficacy in Diabetics INSPIRE-1 (Italian Nobori Stent ProspectIve REgistry-1) San Raffaele Scientific Institute Clinica Mediterranea Istituto Clinico Città Studi IRCCS Policlinico san Donato EMO-GVM Centro Cuore Columbus Ospedali Riuniti Marche Nord Ospedale San Giovanni di Dio Ospedale San Pietro, FBF Ospedale Santa Corona San Raffaele Scientific Institute Humanitas Clinical Institute Clinica Mediterranea Ospedali Riuniti Marche Nord EMO-GVM Centro Cuore Columbus Policlinico Umberto I Ospedale San Paolo
18 Matched analysis: Cre8 vs. BES
19 Matched analysis: Cre8 vs. BES in Diabetics TLF TLR -62% -57%
20 Can DES platform design contribute to maximize efficacy?
21 Drug concentration and DES strut location Vessel wall 3. Over a specific distance from the release point, the drug is no more detected Blood 1. Maximum concentration is achieved next to the DES strut 2. Drug concentration decreases in function of the ability of the drug to permeate the vessel tissue A drug eluted alone has limited permeation into the vessel tissue Closer struts allow for better drug coverage of the vessel wall!!!
22 DRUG EFFICACY MATRIX - Example Geometrical Solution (closer struts)
23 Cre8 EVO: New Stent Architecture
24 New Stent Architecture: more flexibility & higher efficacy An innovative stent architecture has been developed to improve even more the homogeneous drug distribution within the vessel wall, in particular in case of complex coronary anatomies and pathologies like those of diabetic patients New stent architecture
25 Pharmaceutical Solution (Amphilimus TM formulation) DRUG EFFICACY MATRIX Geometrical Solution (Reserviors located closer to each others) Cre8 TM Cre8 TM EVO
26 New Stent Architecture The New Stent Architecture, coupled with Abluminal Reservoirs and Amphilimus TM formulation, has been designed for a uniform drug concentration
27 Second-generation drug-eluting stents in diabetes: a Randomized trial (the SUGAR trial) All-comer patients with diabetes mellitus undergoing PCI Amphilimuseluting stents ~1400 patients ~30 Centers in Spain Randomization 1:1 Zotarolimuseluting stent PI: Rafael Romaguera Primary Endpoint: Non-inferior 12 months Target Vessel Failure (TVF) * Study promoted and funded by the Spanish Society of Cardiology
28 Diab8 randomized trial Study design for superiority All-comer patients with diabetes mellitus undergoing PCI Cre8 TM EVO ~2200 patients ~50 International Sites Randomization 1:1 PI: Antonio Colombo Everolimus Eluting Stent (EES) Primary Endpoint: 12 months Target Lesion Failure (TLF) for superiority Clinical FU 1year 3years
29 Conclusions Diabetes represent today a global emergency. Patients with DM are at high risk of coronary events after PCI with the current DES technology. The Amphilimus TM formulation, eluted in a very controlled way from Abluminal Reservoirs, allows for a very effective neo-intimal inhibition as shown in randomized trials, matched analysis and all-comer studies. Cre8 EVO, with its innovative architecture, can further advance DES efficacy specifically in complex patients. The ongoing randomized trials will evaluate how much patients with DM can benefit from this unique technologies.
TNT Session. The latest clinical evidence in diabetics for the Amphilimus TM eluting polymer-free DES. Rafael Romaguera, MD
TNT Session The latest clinical evidence in diabetics for the Amphilimus TM eluting polymer-free DES Rafael Romaguera, MD Hospital de Bellvitge Barcelona Spain Disclosure Statement of Financial Interest
More informationThe choice of a unique formulation, coupled with a prolonged polymerfree elution, maximizes DES efficacy. R. Byrne Deutsches Herzzentrum München
The choice of a unique formulation, coupled with a prolonged polymerfree elution, maximizes DES efficacy R. Byrne Deutsches Herzzentrum München Disclosures Lecture fees: B. Braun Melsungen, Biotronik,
More informationThe PARTICIPATE trial Prove ART (Abluminal Reservoir Technology) clinical benefit in all comers PATiEnts
The PARTICIPATE trial Prove ART (Abluminal Reservoir Technology) clinical benefit in all comers PATiEnts A multicentre, multinational trial in a large cohort of patients comparable to the everyday clinical
More informationNobori Clinical Studies Up-dates. Gian Battista DANZI, M.D. Ospedale Maggiore Policlinico University of Milan, Italy
Nobori Clinical Studies Up-dates Gian Battista DANZI, M.D. Ospedale Maggiore Policlinico University of Milan, Italy Drug Eluting Stents High benefit in preventing restenosis and improving quality of life
More informationPieter Stella, MD, PhD
A Permanent Polymer Zotarolimus-eluting Stent versus a Polymer-Free Amphilimus-eluting Stent in all-comers; Results of the ReCre8 Trial Pieter Stella, MD, PhD On behalf of the ReCre8 Study investigators
More informationThe latest treatment approach and current developments in SFA
The latest treatment approach and current developments in SFA Dierk Scheinert, MD Department for Interventional Angiology University-Hospital Leipzig, Germany Disclosure Statement of Financial Interest
More informationMoins de 6 mois d antiagrégants après DES?
Moins de 6 mois d antiagrégants après DES? High Tech - Marseille 25 au 27 janvier 2011 Marie-Claude MORICE, MD, FESC, FACC Massy, France Pas de conflit d interet Was optimal duration of DAPT already established
More informationBiosensors Lunch Symposium
Are Current DES the Final Answer? BioFreedom TM : the Polymer-Free Biolimus A9TM Coated Stent Biosensors Lunch Symposium 25 th April 2013 Prof. Stephen WL Lee, JP 李偉聯 MD FRCP(Lon. Edin. Glas.) FHKCP FHKAM
More informationTaking DES technology from concept to long term clinical evidence. Aurore Bouvier Global Product Manager Biosensors Europe
Taking DES technology from concept to long term clinical evidence Aurore Bouvier Global Product Manager Biosensors Europe My conflicts of interest are: Full time employee of Biosensors Europe SA BA9 shows
More informationUltimaster clinical results in left main and bifurcations
Left main and complex bifurcation stenting clinical results in left main and bifurcations GENNARO SARDELLA MD, FACC,FESC O.U. of Interventional Cardiology Dept. of Cardiovascular and Pulmonary Sciences
More informationHCS Working Group Seminars Macedonia Pallas Hotel, Friday 21 st February Drug-eluting stents Are they all equal?
HCS Working Group Seminars Macedonia Pallas Hotel, Friday 21 st February 2014 Drug-eluting stents Are they all equal? Vassilis Spanos Interventional Cardiologist, As. Director 3 rd Cardiology Clinic Euroclinic
More informationResolute in Bifurcation Lesions: Data from the RESOLUTE Clinical Program
Resolute in Bifurcation Lesions: Data from the RESOLUTE Clinical Program Prof. Ran Kornowski, MD, FESC, FACC Director - Division of Interventional Cardiology Rabin Medical Center and Tel Aviv University,
More informationCOMPARE Trial Elvin Kedhi Maasstad Ziekenhuis Rotterdam The Netherlands
COMPARE Trial Elvin Kedhi Maasstad Ziekenhuis Rotterdam The Netherlands TCTAP 2010 Seoul, Korea Disclosures Research Foundation of the Cardiology Department has received unrestricted research grants from:
More informationBIOFREEDOM: Polymer free Biolimus A9 eluting
TCTAP 2011 Seoul, April 27 29, 2011 BIOFREEDOM: Polymer free Biolimus A9 eluting Stents and Paclitaxel eluting stents Eberhard Grube MD, FACC, FSCAI Hospital Oswaldo Cruz - Dante Pazzanese, São Paulo,
More informationNew Generation Drug- Eluting Stent in Korea
New Generation Drug- Eluting Stent in Korea Young-Hak Kim, MD, PhD Department of Cardiology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea Purpose To briefly introduce the
More informationDISCOVER Ultimaster with Optical Frequency Domain Imaging
DISCOVER Ultimaster with Optical Frequency Domain Imaging David Hildick-Smith Sussex Cardiac Centre Brighton and Sussex University Hospitals United Kingdom Potential conflicts of interest Speaker's name:
More informationBioresorbable polymer drug-eluting stents in PCI
EARN 3 FREE CPD POINTS CARDIOVASCULAR Leader in digital CPD for Southern African healthcare professionals The BIOFLOW-V trial, using the Orsiro ultrathin strut stent with biodegradable polymer, showed
More informationeluting Stents The SPIRIT Trials
Everolimus-eluting eluting Stents The SPIRIT Trials Gregg W. Stone, MD Columbia University Medical Center Cardiovascular Research Foundation Abbott XIENCE V Everolimus-eluting eluting Stent Everolimus
More informationThree-Year Clinical Outcomes with Everolimus-Eluting Bioresorbable Scaffolds: Results from the Randomized ABSORB III Trial Stephen G.
Three-Year Clinical Outcomes with Everolimus-Eluting Bioresorbable Scaffolds: Results from the Randomized ABSORB III Trial Stephen G. Ellis MD Dean J. Kereiakes MD and Gregg W. Stone MD for the ABSORB
More informationBiolimus A9 Drug-Eluting Stents: Technical Aspects and a Comprehensive Review of the EU, Asia-Pacific, and US Clinical Trial Program
TCT Asia 2006 Biolimus A9 Drug-Eluting Stents: Technical Aspects and a Comprehensive Review of the EU, Asia-Pacific, and US Clinical Trial Program Eberhard Grube MD FACC, FSCAI HELIS Heart Center Siegburg,
More informationPCI with Polymer-free Stent
PCI with Polymer-free Stent Florian Krackhardt, M.D. Department of Cardiology Charité Campus Virchow-Klinikum University Hospital Berlin, Germany Drug Eluting Stents: Present Coating Technology Solution
More informationBiolimus-Eluting Stent With Biodegradable Polymer Versus Sirolimus-Eluting Stent With Durable Polymer: A Randomised, Non-Inferiority Trial
Limus Eluted From A Durable vs ERodable Stent Coating Biolimus-Eluting Stent With Biodegradable Polymer Versus Sirolimus-Eluting Stent With Durable Polymer: A Randomised, Non-Inferiority Trial Stephan
More informationBernard Chevalier Institut Jacques Cartier, Massy, France. Patrick W. Serruys Imperial College, London, UK Erasmus University MC, Netherlands
The 4-year Clinical Outcomes of the ABSORB II Trial: First Randomized Comparison between the Absorb Everolimus Eluting Bioresorbable Vascular Scaffold and the Everolimus Eluting Stent Bernard Chevalier
More informationInspiron Stent. Clinical Research Program. Pedro A. Lemos MD PhD. Heart Institute InCor University of Sao Paulo Medical School Sao Paulo Brazil
Stent Clinical Research Program Pedro A. Lemos MD PhD Heart Institute InCor University of Sao Paulo Medical School Sao Paulo Brazil All faculty disclosures are available on the CRF Events App and online
More informationPolymer-Free Stent CX - ISAR
Polymer-Free Stent CX - ISAR Moo Hyun Kim, MD, FACC on behalf of Dr. Florian Krackhardt, Germany CX ISAR Stent : Features Intracoronary Stenting and Angiographic Results Strut Thickness of only 50/60 μm
More information2-year outcome of the 3-arm BIO-RESORT randomized trial in all-comer patients treated with contemporary DES
2-year outcome of the 3-arm BIO-RESORT randomized trial in all-comer patients treated with contemporary DES Marlies M. Kok, MD Thoraxcentrum Twente, MST, Enschede, the Netherlands On behalf of the BIO-RESORT
More informationBifurcation Stenting: IVUS and OCT Information
Bifurcation Stenting: IVUS and OCT Information Yoshinobu Murasato MD, PhD (New Yukuhashi Hospital) On behalf of J-REVERSE investigators October 14-15, 2011, Lisbon Proximal stent deformation induced by
More informationSecond Generation Drug Eluting Stents: From Inhibition to Healing
Second Generation Drug Eluting Stents: From Inhibition to Healing Mitchell W. Krucoff MD, FACC Professor of Medicine / Cardiology Duke University Medical Center Director, Cardiovascular Devices Unit Duke
More informationNOBORI 2 Trials One Year Clinical Outcomes
NBRI 2 Trials ne Year Clinical utcomes Dr G.B. Danzi spedale Maggiore Policlinico Milano, Italy INTRDUCTIN Pivotal DES trials enrolled restricted patient population, not truly representative of every day
More informationBernard Chevalier Institut Jacques Cartier, Massy, France. Patrick W. Serruys Imperial College, London, UK Erasmus University MC, Netherlands
The 4-year Clinical Outcomes of the ABSORB II Trial: First Randomized Comparison between the Absorb Everolimus Eluting Bioresorbable Vascular Scaffold and the XIENCE Everolimus Eluting Stent Bernard Chevalier
More informationCYPHER (Polymer-based Sirolimus-eluting DES) New Stent Platforms. Campbell Rogers, M.D. Chief Technology Officer
Ground breaking, Life changing CYPHER (Polymer-based Sirolimus-eluting DES) New Stent Platforms Campbell Rogers, M.D. Chief Technology Officer Disclosure Statement of Financial Interest I am a full-time
More informationBIOFLOW-III an all comers registry with a Sirolimus Eluting Stent: Presentation of 1-Year TLF Data in patients with complex lesions
BIOFLOW-III an all comers registry with a Sirolimus Eluting Stent: Presentation of 1-Year TLF Data in patients with complex lesions Johannes Waltenberger, MD, F.E.S.C. Uniklinik Münster Münster, Germany
More informationDES in Diabetic Patients
DES in Diabetic Patients Charles Chan, M.D., FACC Gleneagles Hospital Singapore TCT ASIA PACIFIC 2007 Why do diabetics have worse outcome after PCI? More extensive atherosclerosis and diffuse disease Increase
More informationBIOFLOW by Orsiro stents
BIOFLOW by stents Byeong-Keuk Kim, MD, PhD Division of Cardiology, Department of Internal Medicine, Severance Cardiovascular Hospital, Yonsei University College of Medicine Key Benefits Clinically proven
More informationCoroflex ISAR. Sirolimus Eluting Polymer-Free Coronary Stent System. Vascular Systems
Coroflex ISAR Sirolimus Eluting Polymer-Free Coronary Stent System Vascular Systems Coroflex ISAR Polymer-Free Drug Coating Complete Drug Release Sirolimus Established anti-inflammatory and anti-proliferative
More informationInsight from the CACTUS trial Coronary Bifurcation Application of the Crush
EBC - Prague 26-28 september 2008 Insight from the CACTUS trial The role of final kissing balloon inflation F. Airoldi,, A. Colombo San Raffaele Scientific Institute EMO Centro Cuore,, Columbus Hospital
More informationINDEX 1 INTRODUCTION DEVICE DESCRIPTION CLINICAL PROGRAM FIRST-IN-MAN CLINICAL INVESTIGATION OF THE AMAZONIA SIR STENT...
May 2017 INDEX 1 INTRODUCTION... 2 2 DEVICE DESCRIPTION... 3 ANTI-PROLIFERATIVE DRUG - SIROLIMUS... 3 BIODEGRADABLE POLYMERS... 3 SIROLIMUS CONTROLLED ELUTION... 4 STENT PLATFORM... 4 3 CLINICAL PROGRAM...
More informationA Polymer-Free Dual Drug-Eluting Stent in Patients with Coronary Artery Disease: Randomized Trial Versus Polymer-Based DES.
A Polymer-Free Dual Drug-Eluting Stent in Patients with Coronary Artery Disease: Randomized Trial Versus Polymer-Based DES ISAR-TEST 2 Trial Robert A. Byrne, MB MRCPI Deutsches Herzzentrum and 1. Med.
More informationISAR-LEFT MAIN 2 Randomized Trial. Zotarolimus- vs. Everolimus-Eluting Stents for Treatment of Unprotected Left Main Coronary Artery Lesions
ISAR-LEFT MAIN 2 Randomized Trial Zotarolimus- vs. Everolimus-Eluting Stents for Treatment of Unprotected Left Main Coronary Artery Lesions Julinda Mehilli, MD Klinikum der Universitaet Munich Deutsches
More informationCurrent Status of BioresorbableScaffolds: Moving Forward or Backwards?
Evolving Science of Stents Current Status of BioresorbableScaffolds: Moving Forward or Backwards? Christian W. Hamm Kerckhoff Heart and Thorax Center Bad Nauheim and Medical Clinic I, University of Giessen,
More informationEXCEL vs. NOBLE: How to Treat Left Main Disease in 2017 AATS International Cardiovascular Symposium December 8-9, 2017
EXCEL vs. NOBLE: How to Treat Left Main Disease in 2017 AATS International Cardiovascular Symposium December 8-9, 2017 Igor F. Palacios, MD Director of Interventional Cardiology Professor of Medicine Massachusetts
More informationOCT Technology: Differences between Biodegradable and Durable Polymers: Insights from the LEADERS Trial LEADERS OCT
OCT Technology: Differences between Biodegradable and Durable Polymers: Insights from the LEADERS Trial LEADERS OCT Substudy Carlo Di Mario, MD Peter Barlis, MD Evelyn Regar, MD Peter Juni, MD Patrick
More informationStephen G. Ellis, M.D. Professor of Medicine Director Invasive Services Co-Director Cardiac Gene Bank
From ABSORB Cohort A to ABSORB III and IV Randomized Trials Stephen G. Ellis, M.D. Professor of Medicine Director Invasive Services Co-Director Cardiac Gene Bank Disclosures Consultant, Abbott Vascular
More informationSKG Congress, 2015 EVOLVE II. Stephan Windecker
SKG Congress, 2015 EVOLVE II Stephan Windecker Department of Cardiology Swiss Cardiovascular Center and Clinical Trials Unit Bern Bern University Hospital, Switzerland BIODEGRADABLE POLYMER DES Stefanini,
More informationDual-therapy stent technology for patients with coronary artery disease Kalkman, D.N.
UvA-DARE (Digital Academic Repository) Dual-therapy stent technology for patients with coronary artery disease Kalkman, D.N. Link to publication Citation for published version (APA): Kalkman, D. N. (2018).
More informationDrug eluting stents. Where are we now and what can we expect in 2003? Tony Gershlick Leicester
Drug eluting stents Where are we now and what can we expect in 2003? Tony Gershlick Leicester Trials Real World What we need i. Prevent restenosis cost effective Either : - Treat all at equivalent cost
More informationFrom a DES to a BMS* Biosensors Clinical Trial Program. Taking the LEAD in DES Clinical Excellence. From Single de Novo.
Biosensors Clinical Trial Program Taking the LEAD in DES Clinical Excellence Our trials gather clinical data for this technology from a wide range of patients, including those with single de novo lesions,
More information7-Year Follow-up From a Randomized Trial of Sirolimus-Eluting vs. Everolimus-Eluting Stents in Patients With Coronary Artery Disease (RESET)
7-Year Follow-up From a Randomized Trial of Sirolimus-Eluting vs. Everolimus-Eluting Stents in Patients With Coronary Artery Disease (RESET) Hiroki Shiomi, MD Kyoto University Graduate School of Medicine
More informationUpdate from the Tryton IDE study
Update from the Tryton IDE study Maciej Lesiak EBC 2015 - Athens The Tryton Bifurcation Trial: A randomized comparison of a provisional one-stent vs. a dedicated two-stent strategy for true bifurcation
More information2-Year Follow-Up of a Randomized Controlled Trial of Everolimus- and Paclitaxel-Eluting Stents for Coronary Revascularization in Daily Practice
Journal of the American College of Cardiology Vol. 58, No. 1, 2011 2011 by the American College of Cardiology Foundation ISSN 0735-1097/$36.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2011.02.023
More informationYukon Chrome PC. Translumina trust is what counts. Sirolimus Eluting CoCr Coronary Stent System. 5-Years Randomized Clinical Follow-Up
Sirolimus Eluting CoCr Coronary Stent System Yukon Chrome PC 5-Years Randomized Clinical Follow-Up Translumina trust is what counts trust is what counts Yukon Chrome PC DES coating with excellent long-term
More informationBIOFLOW V Comparison of UltraThin Sirolimus-Eluting Bioresorbable Polymer with Thin Everolimus- Eluting Durable Polymer Stents
Comparison of UltraThin Sirolimus-Eluting Bioresorbable Polymer with Thin Everolimus- Eluting Durable Polymer Stents David E Kandzari, MD; Laura Mauri, MD, MSc; Jacques Koolen, MD, PhD; Joseph M Massaro,
More informationDrug eluting balloons in CAD
Drug eluting balloons in CAD Ioannis Iakovou, MD, PhD Interventional Cardiology 1 st Cath Lab Onassis Cardiac Surgery Center Drug-Eluting Balloons (DEB) Technology and Applications 1. Special Features
More informationBioabsorbable stents: early clinical results. Dr Angela Hoye MB ChB, PhD Senior Lecturer in Cardiology Hull & East Yorkshire Hospitals
Bioabsorbable stents: early clinical results Dr Angela Hoye MB ChB, PhD Senior Lecturer in Cardiology Hull & East Yorkshire Hospitals MY CONFLICTS OF INTEREST ARE: Clinical Events Committee member for
More informationPatrick W. Serruys MD. PhD. 1 Bernard Chevalier MD. 2 Yoshinobu Onuma MD. PhD. 3 on behalf of ABSORB II investigators
TCT 216, Washington convention center October 3 th 216, 8:3 am- Room 159 Level 1 Late breaking clinical trial and First report investigations Press Conf.1 ABSORB II: Three-year Clinical Outcomes from a
More informationElement Clinical Program Perseus Late Breaking News and the Platinum Study Design
Element Clinical Program Perseus Late Breaking News and the Platinum Study Design Ian T. Meredith MBBS, BSc(Hons), Ph.D, FRACP, FACC, FCSANZ, FSCAI, FAHA, FAPSIC Professor and Director of Monash HEART
More informationDrug eluting stents From revolution to evolution. Current limitations
Drug eluting stents From revolution to evolution Current limitations Eric Eeckhout Centre Hospitalier Universitaire Vaudois Lausanne - Switzerland eric.eeckhout@chuv.ch Overview Historical perspective
More informationTailored bifurcation therapy
Tailored bifurcation therapy Dedicated self-expanding platform that conforms to the specific bifurcation anatomy Full bifurcation lesion coverage without creating a false carina Bifurcation DES technology
More informationBackground. Drug-eluting stents (DES) are increasingly used in complex patients with a high clinical or lesion-related risk of adverse events.
Complex Patients Treated with Second- Generation Zotarolimus-Eluting Resolute and Everolimus-Eluting Xience V Stents in the Randomized TWENTE Trial: Comparison of 2- Year Clinical Outcome Hanim Sen, MD
More informationTIDES-ACS trial. Comparison of TItanium-nitride-oxide coated bioactive stent to the Drug (everolimus)-eluting Stent in Acute Coronary Syndrome
TIDES-ACS trial Comparison of TItanium-nitride-oxide coated bioactive stent to the Drug (everolimus)-eluting Stent in Acute Coronary Syndrome Pasi P Karjalainen Potential conflicts of interest Speaker's
More informationPROMUS Element Experience In AMC
Promus Element Luncheon Symposium: PROMUS Element Experience In AMC Jung-Min Ahn, MD. University of Ulsan College of Medicine, Heart Institute, Asan Medical Center, Seoul, Korea PROMUS Element Clinical
More informationEffect of Intravascular Ultrasound- Guided vs. Angiography-Guided Everolimus-Eluting Stent Implantation: the IVUS-XPL Randomized Clinical Trial
Effect of Intravascular Ultrasound- Guided vs. Angiography-Guided Everolimus-Eluting Stent Implantation: the IVUS-XPL Randomized Clinical Trial Myeong-Ki Hong, MD. PhD on behalf of the IVUS-XPL trial investigators
More informationIN-STENT RESTENOSIS. K.Boerlage-van Dijk CarVasZ 2014
IN-STENT RESTENOSIS K.Boerlage-van Dijk CarVasZ 2014 Definition ISR Angiographic: recurrent diameter stenosis >50% at the stent segment or edges (5-mm segments adjacent to stent) Mehran system morphological
More informationBioabsorbable Scaffolding: Technology and Clinical Update. PD Dr. Nicolas Diehm, MD, FESC Inselspital, University Hospital Bern, Switzerland
Bioabsorbable Scaffolding: Technology and Clinical Update PD Dr. Nicolas Diehm, MD, FESC Inselspital, University Hospital Bern, Switzerland Disclosures I am not Ron Waksman 1 Clinical experience with AMS
More informationINTERVENTIONAL VASCULAR DIAGNOSTICS AND THERAPY. SeQuent Please NEO CLINICAL EVIDENCE AND COST / BENEFIT EFFECTIVENESS
INTERVENTIONAL VASCULAR DIAGNOSTICS AND THERAPY SeQuent Please NEO CLINICAL EVIDENCE AND COST / BENEFIT EFFECTIVENESS Table of Contents Overview SeQuent Please - DCB Scientific Publications SeQuent Please
More informationANGIOPLASY SUMMIT 2007 TCT ASIA PACIFIC. Seoul, Korea: April Session: Left mains & bifurcation intervention
ANGIOPLASY SUMMIT 2007 TCT ASIA PACIFIC Seoul, Korea: 25-27 27 April 2007 Session: Left mains & bifurcation intervention An integrated approach to bifurcation lesions: lessons from years of randomized
More informationRun-Lin Gao, MD, FACC. On Behalf of I-LOVE-IT Trial Investigators
I-LOVE-IT A Prospective, Multicenter Clinical Trial of TIVOLI Bioabsorbable Polymer Based Sirolimus-Eluting vs. ENDEAVOR Zotarolimus- Eluting Stent in Patients with Coronary Artery Disease: 8-Month Angiographic
More informationThe Vascular Concepts - PRONOVA Durable Polymer Sirolimus Eluting Stent A Review of Indian Registry Results
The Vascular Concepts - PRONOVA Durable Polymer Sirolimus Eluting Stent A Review of Indian Registry Results Dr. VIVEK GUPTA MD, DM, FICC, FIC France Senior Interventional Cardiologist Indraprastha Apollo
More informationDrug Eluting Stent Summit-II. The Program of DES of SORIN. Gian B. Danzi Poliambulanza Hospital Brescia- ITALY
Drug Eluting Stent Summit-II The Program of DES of SORIN Gian B. Danzi Poliambulanza Hospital Brescia- ITALY The Program of DES of SORIN The platform The drug Animal data Clinical studies Drug Eluting
More informationKomplexe Koronarintervention heute: Von Syntax zu bioresorbierbaren Stents
Komplexe Koronarintervention heute: Von Syntax zu bioresorbierbaren Stents Prof. Dr. med. Julinda Mehilli Medizinische Klinik und Poliklinik I Klinikum der Universität München Campus Großhadern Key Factors
More informationTwo-Year Outcomes of High Bleeding Risk Patients after Polymer-Free Drug-Coated Stents
Two-Year Outcomes of High Bleeding Risk Patients after Polymer-Free Drug-Coated Stents Philip Urban, Philippe Garot, Damras Tresukosol, Stuart J. Pocock, Ian Meredith, Alex Abizaid, Didier Carrié, Christoph
More informationANGIOPLASY SUMMIT 2007 TCT ASIA PACIFIC. Seoul, Korea: April The problem is exaggerated: Data from Real World Registries
ANGIOPLASY SUMMIT 007 TCT ASIA PACIFIC Seoul, Korea: 5-7 7 April 007 15 min Plenary Session: State-of of-the-art Lectures The problem is exaggerated: Data from Real World Registries Antonio Colombo Centro
More informationSirolimus Nanocrystal Balloon Based Delivery for Coronary DES ISR
Sirolimus Nanocrystal Balloon Based Delivery for Coronary DES ISR DR. SAMEER I DANI Director, Department of Cardiology, Apollo Hospital & Life Care Institute (LIMSAR), Ahmedabad, India. IN STENT RESTENOSIS
More informationDr. Robert J. van Geuns. Thoraxcenter ErasmusMC Rotterdam On behalf of Dr. Jean Fajadet and Co-investigators
Complex coronary bifurcation lesions treated with the novel polymer-free dedicated bifurcation paclitaxel-eluting stent (Nile pax): clinical and angiographic results of the prospective, multicenter bipax
More informationFreedom to Treat Your High Bleeding Risk Patients. Tim Kinnaird University Hospital of Wales, Cardiff, UK
Freedom to Treat Your High Bleeding Risk Patients Tim Kinnaird University Hospital of Wales, Cardiff, UK Relevant Disclosures Honoraria for lectures from: o Eli Lilly & Co, Daiichi Sankyo, Boehringer,
More informationPatrick W. Serruys Imperial College, London, UK Erasmus University MC, Rotterdam, the Netherlands
TCT 2014 13 Sep 2014-17 Sep 2014, Washington, DC - U.S.A Plenary Session XII : Late-Breaking clinical Trials #2 ABSORB II : A Prospective, Randomized Trial of an Everolimus-Eluting Bioresorbable Scaffold
More informationDrug Filled Stent Optical Coherence Tomography Results from RevElution Trial Stent Strut Coverage and Stent Apposition
Drug Filled Stent Optical Coherence Tomography Results from RevElution Trial Stent Strut Coverage and Stent Apposition Prof Martin Rothman on behalf of Dr. Stephen G. Worthley Alexandre Abizaid, Ajay J
More informationZotarolimus- and Paclitaxel-Eluting Stents in an All-Comer Population in China
JACC: CARDIOVASCULAR INTERVENTIONS VOL. 6, NO. 7, 2013 2013 BY THE AMERICAN COLLEGE OF CARDIOLOGY FOUNDATION ISSN 1936-8798/$36.00 PUBLISHED BY ELSEVIER INC. http://dx.doi.org/10.1016/j.jcin.2013.03.001
More informationSession: DEB their Utility. Innovation in Drug Coated Balloons
Session: DEB their Utility 2 nd MARCH 2014 Innovation in Drug Coated Balloons Dr. Upendra Kaul Fortis Escorts Heart Institute New Delhi Disclosure I, Upendra Kaul, do not have a financial interest/arrangement
More informationYukon Choice PC Translumina trust is what counts
Sirolimus Eluting Coronary Stent System 5-Years Randomized Clinical Follow-Up Translumina trust is what counts trust is what counts DES with excellent long-term clinical outcome The Translumina PC drug-eluting
More informationProvisional T- sten/ng Future Outlook: Ra/onale of Plaque Incision + DCB
Provisional T- sten/ng Future Outlook: Ra/onale of Plaque Incision + DCB Dr. Azeem La/b EMO- GVM Centro Cuore Columbus and San Raffaele Scien/fic Ins/tute, Milan, Italy PCI in Coronary Bifurca/ons Up to
More informationThe essentials for BTK procedures: wires, balloons, what else
A comprehensive approach to diabetic patient Tx The essentials for BTK procedures: wires, balloons, what else Dai-Do Do Clinical and Interventional Angiology Cardiovascular Department Disclosure Speaker
More informationEXAMINATION trial. Manel Sabaté Hospital Clínic, Barcelona (On behalf of the Examination Investigators)
Manel Sabaté Hospital Clínic, Barcelona (On behalf of the Examination Investigators) Disclosures Investigator Initiated Trial: NCT00828087. Unrestricted grant from Abbott to the Spanish Heart Foundation.
More informationResults of TROFI II Study. Patrick W. Serruys, MD, PhD. Imperial college, London, UK On behalf of the PI s and the TROFI II investigators
Comparison of the ABSORB TM Everolimus Eluting Bioresorbable Vascular Scaffold System With a Drug- Eluting Metal Stent (Xience TM ) in Acute ST-Elevation Myocardial Infarction: Results of TROFI II Study.
More informationPeriprocedural Myocardial Infarction and Clinical Outcome In Bifurcation Lesion
Periprocedural Myocardial Infarction and Clinical Outcome In Bifurcation Lesion Hyeon-Cheol Gwon Cardiac and Vascular Center Samsung Medical Center Sungkyunkwan University School of Medicine Dr. Hyeon-Cheol
More informationMid-term results from real-world REPARA registry. Felipe Hernandez, on behalf of the REPARA investigators
Mid-term results from real-world REPARA registry Felipe Hernandez, on behalf of the REPARA investigators Potential conflicts of interest Speaker's name: Felipe Hernandez I have the following potential
More informationIan T. Meredith AM. MBBS, PhD, FRACP, FCSANZ, FACC, FSCAI, FAPSIC MonashHeart, Monash Medical Centre & Monash University Melbourne, Australia
Final five-year clinical outcomes in the EVOLVE trial: A randomised evaluation of a novel bioabsorbable polymer-coated, everolimus-eluting stent Ian T. Meredith AM MBBS, PhD, FRACP, FCSANZ, FACC, FSCAI,
More informationUtilities and Pitfalls of Composite and Surrogate Endpoints in Clinical Trials. Cardiovascular Research Foundation Columbia University Medical Center
Utilities and Pitfalls of Composite and Surrogate Endpoints in Clinical Trials Helen Parise,, ScD Cardiovascular Research Foundation Columbia University Medical Center Common CV Clinical Endpoints Death
More informationTCTAP Upendra Kaul MD,DM,FACC,FSCAI,FAMS,FCSI
Indian TUXEDO Trial In Medically Treated Diabetics Upendra Kaul MD,DM,FACC,FSCAI,FAMS,FCSI Executive Director and Dean Escorts Heart Institute & Medical Research Center and Fortis Hospitals, New Delhi
More informationThe BIO revolution: bioadsorbable stents. Federico Conrotto Cardiologia 2 Città della Salute e della Scienza di Torino
The BIO revolution: bioadsorbable stents Federico Conrotto Cardiologia 2 Città della Salute e della Scienza di Torino BVS stent (Abbot Vascular) Strut Material: Poly-L-Lactic acid Coating Material: Poly-D,L-lactide
More informationEvaluation COMBO s Healing Profile The EGO-COMBO Serial OCT Study
Evaluation COMBO s Healing Profile The EGO-COMBO Serial OCT Study OrbusNeich Dual Therapy COMBO Stent Symposium 25 th April 2013 Prof. Stephen WL Lee, JP 李偉聯 MD FRCP(Lon. Edin. Glas.) FHKCP FHKAM FACC
More informationPCI for In-Stent Restenosis. CardioVascular Research Foundation
PCI for In-Stent Restenosis ISR of BMS Patterns of In-Stent Restenosis Pattern I : Focal Type IA: Articulation / Gap Type IB: Marginal Type IC: Focal body Type ID: Multifocal Pattern II,III,IV : Diffuse
More informationDrug Eluting Stents Sometimes Fail ESC Stockholm 29 Set 2010 Stent Thrombosis Alaide Chieffo
Drug Eluting Stents Sometimes Fail ESC Stockholm 29 Set 2010 Stent Thrombosis 11.45-12.07 Alaide Chieffo San Raffaele Scientific Institute, Milan, Italy Historical Perspective 25 20 15 10 5 0 Serruys 1991
More informationResults of TROFI II Study. Patrick W. Serruys, MD, PhD. Imperial college, London, UK On behalf of the PI s and the TROFI II investigators
Comparison of the ABSORB TM Everolimus Eluting Bioresorbable Vascular Scaffold System With a Drug- Eluting Metal Stent (Xience TM ) in Acute ST-Elevation Myocardial Infarction: Results of TROFI II Study.
More informationBern-Rotterdam Cohort Study
Bern-Rotterdam Cohort Study Newer generation everolimus-eluting stents eliminate the risk of very late stent thrombosis compared with early generation sirolimus-eluting and paclitaxel-eluting stents Lorenz
More informationInnovation in Cardiovascular Interventions. New DES, Scaffolds and other Devices Have Angioplasty Results Improved
Innovation in Cardiovascular Interventions New DES, Scaffolds and other Devices Have Angioplasty Results Improved Alexandra Lansky, MD Yale University School of Medicine University College of London DES
More informationDESolve NX Trial Clinical and Imaging Results
DESolve NX Trial Clinical and Imaging Results Alexandre Abizaid, MD, PhD, Instituto Dante Pazzanese, Sao Paulo, Brazil On behalf of the DESolve Nx Trial Investigators Please refer to the TCT2014 App or
More informationPCI for Long Coronary Lesion
PCI for Long Coronary Lesion Shift of a General Idea with the Introduction of DES In the Bare Metal Stent Era Higher Restenosis Rate With Increasing Stent Length and Decreasing Stent Area Restenosis.6.4.2
More informationLM stenting - Cypher
LM stenting - Cypher Left main stenting with BMS Since 1995 Issues in BMS era AMC Restenosis and TLR (%) 3 27 TLR P=.282 Restenosis P=.71 28 2 1 15 12 Ostium 5 4 Shaft Bifurcation Left main stenting with
More information